BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews 2014;28:67-74. [DOI: 10.1016/j.blre.2014.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med 2015;277:294-305. [PMID: 25495259 DOI: 10.1111/joim.12338] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
2 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
3 Enjeti AK, de Malmanche T, Chapman K, Ziolkowski A. Genomic investigation of inherited thrombotic microangiopathy-aHUS and TTP. Int J Lab Hematol 2020;42 Suppl 1:33-40. [PMID: 32543063 DOI: 10.1111/ijlh.13201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, York S, Brodsky RA. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol 2016;44:390-8. [PMID: 26921648 DOI: 10.1016/j.exphem.2016.01.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
5 Alhabhbeh A, Fatima Z, Thomas A, Cook C. Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult. Cureus 2021;13:e18184. [PMID: 34589371 DOI: 10.7759/cureus.18184] [Reference Citation Analysis]
6 Lara JP, Santana Y, Gaddam M, Ali A, Malik S, Khaja M. Diclofenac-induced thrombotic thrombocytopenic purpura with concomitant complement dysregulation: a case report and review of the literature. J Med Case Rep 2019;13:190. [PMID: 31228952 DOI: 10.1186/s13256-019-2097-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Boneparth A, Moorthy LN, Weiss L, Rajasekhar H, Murphy S, Drachtman RA. Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura. Glob Pediatr Health 2015;2:2333794X15570150. [PMID: 27335943 DOI: 10.1177/2333794X15570150] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Vaughn JL, Moore JM, Cataland SR. Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Rep Hematol 2015;2015:327980. [PMID: 26557394 DOI: 10.1155/2015/327980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Chen SF, Wang FM, Li ZY, Yu F, Chen M, Zhao MH. The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis. Clin Immunol 2017;175:41-50. [PMID: 27939215 DOI: 10.1016/j.clim.2016.11.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, Wu HM. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura: Diagnostic and Prognostic Values of ADAMTS13 during PE Therapy. Transfusion 2015;55:18-24. [DOI: 10.1111/trf.12762] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
11 Tsiakas S, Marinaki S, Lionaki S, Boletis J. Plasma Exchange in ANCA-Associated Vasculitis: A Narrative Review. J Clin Med 2021;10:5154. [PMID: 34768675 DOI: 10.3390/jcm10215154] [Reference Citation Analysis]
12 Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
13 Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica 2017;102:466-75. [PMID: 27810992 DOI: 10.3324/haematol.2016.153312] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
14 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
15 Vaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F, Kok F. Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls. Pediatr Nephrol 2017;32:1089-92. [PMID: 28210839 DOI: 10.1007/s00467-017-3615-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
16 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
17 Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Bone Marrow Transplant 2017;52:1355-60. [PMID: 28287636 DOI: 10.1038/bmt.2017.39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
18 Manook M, Kwun J, Burghuber C, Samy K, Mulvihill M, Yoon J, Xu H, MacDonald AL, Freischlag K, Curfman V, Branum E, Howell D, Farris AB, Smith RA, Sacks S, Dorling A, Mamode N, Knechtle SJ. Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. Am J Transplant 2017;17:2055-64. [PMID: 28226413 DOI: 10.1111/ajt.14234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
19 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
20 Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, Häffner K, Reski R, Decker EL. Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors. Front Plant Sci 2019;10:260. [PMID: 30949184 DOI: 10.3389/fpls.2019.00260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
21 Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, Noris M. ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clin J Am Soc Nephrol 2015;10:2002-12. [PMID: 26342041 DOI: 10.2215/CJN.01700215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
22 Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood 2015;125:3637-46. [PMID: 25862562 DOI: 10.1182/blood-2015-02-629683] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
23 Beris P, Picard V. Non-immune Hemolysis: Diagnostic Considerations. Semin Hematol 2015;52:287-303. [PMID: 26404441 DOI: 10.1053/j.seminhematol.2015.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G. Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. Am J Kidney Dis 2015;66:1067-70. [PMID: 26409664 DOI: 10.1053/j.ajkd.2015.06.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
25 Medeni SS, Namdaroglu S, Cetintepe T, Ozlu C, Tasli F, Adibelli ZH, Bilgir O, Tatar E. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematol Rep 2018;10:7553. [PMID: 30344987 DOI: 10.4081/hr.2018.7553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Noone DG, Riedl M, Licht C. The role of von Willebrand factor in thrombotic microangiopathy. Pediatr Nephrol 2018;33:1297-307. [DOI: 10.1007/s00467-017-3744-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Bomback AS, Markowitz GS, Appel GB. Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways. Kidney Int Rep 2016;1:148-55. [PMID: 29142924 DOI: 10.1016/j.ekir.2016.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
28 Bazzan M, Todros T, Tedeschi S, Ardissino G, Cardaropoli S, Stella S, Montaruli B, Marchese C, Roccatello D, Cugno M. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome. Thromb Res 2020;196:167-74. [PMID: 32890900 DOI: 10.1016/j.thromres.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]